GlassScriptPhysician profile
Ibrahima Goudiaby
NPI 1851639504
$9,629.51
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $1,296 · 2021: $3,146 · 2022: $3,800 · 2023: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,553.91 | 2019-2022 | |
| Amgen INC. | $1,422.45 | 2019-2023 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $1,296.80 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,003.43 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $707.44 | 2019-2023 | Trulicity, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $335.91 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.99 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $325.42 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $318.60 | 2020-2022 | |
| Pfizer INC. | $295.65 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $188.13 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $159.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $148.46 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $147.91 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $137.07 | 2021-2023 | Airduo Digihaler |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahima Goudiaby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.